Ikarian Capital, LLC Alpine Immune Sciences, Inc. Transaction History

Ikarian Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.75 - $41.6 $4.01 Million - $9.4 Million	-225,883 Reduced 46.36%	261,365 $10.4 Million
Q4 2023 Feb 14, 2024	BUY	$8.54 - $20.22 $4.16 Million - $9.85 Million	487,248 New	487,248 $9.29 Million
Q3 2021 Nov 15, 2021	SELL	$8.19 - $11.31 $2.46 Million - $3.4 Million	-300,454 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$8.81 - $15.03 $37,750 - $64,403	-4,285 Reduced 1.41%	300,454 $2.7 Million
Q1 2021 May 17, 2021	BUY	$10.02 - $13.92 $3.01 Million - $4.18 Million	300,000 Added 6330.45%	304,739 $3.23 Million
Q2 2020 Aug 14, 2020	BUY	$2.77 - $12.1 $13,127 - $57,341	4,739 New	4,739 $46,000
Q1 2020 May 15, 2020	SELL	$2.15 - $4.41 $10,188 - $20,898	-4,739 Closed	0 $0
Q4 2019 Jan 31, 2020	BUY	$2.45 - $3.87 $11,610 - $18,339	4,739 New	4,739 $18,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.